Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Advanced, anaplastic lymphoma kinase (ALK)-positive lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhibitors (e.g., ceritinib, alectinib) upon progression. Second-generation inhibitors are generally effective even i...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Cancer Discov
المؤلفون الرئيسيون: Gainor, Justin F., Dardaei, Leila, Yoda, Satoshi, Friboulet, Luc, Leshchiner, Ignaty, Katayama, Ryohei, Dagogo-Jack, Ibiayi, Gadgeel, Shirish, Schultz, Katherine, Singh, Manrose, Chin, Emily, Parks, Melissa, Lee, Dana, DiCecca, Richard H., Lockerman, Elizabeth, Huynh, Tiffany, Logan, Jennifer, Ritterhouse, Lauren L., Le, Long P., Muniappan, Ashok, Digumarthy, Subba, Channick, Colleen, Keyes, Colleen, Getz, Gad, Dias-Santagata, Dora, Heist, Rebecca S., Lennerz, Jochen, Sequist, Lecia V., Benes, Cyril H., Iafrate, A. John, Mino-Kenudson, Mari, Engelman, Jeffrey A., Shaw, Alice T.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2016
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5050111/
https://ncbi.nlm.nih.gov/pubmed/27432227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0596
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة